Director · Mineralys Therapeutics, Inc. · Common Stock
Side
SELL
Value
$226K
Shares
4,885
Price
$46.36
Executed
Nov 13, 2025
Disclosed
Nov 13, 2025
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Nov 13 executedNov 13, 2025 disclosed
MLYS · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 0 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering+15 / 15
4 other actors traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Karydas Daphne filed this Form 4 reporting a open-market sale of MLYS on Nov 13, 2025. It became public on Nov 13, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Karydas Daphnecik:0001816952
Issuer
Mineralys Therapeutics, Inc.cik:0001933414
Revision history · 0
No field has changed since this record was first ingested.
